A new study found that a drug recently approved to treat type 2 diabetes and kidney disease in patients with additional ...

Announcing a new article publication for Cardiovascular Innovations and Applications journal. This study was aimed at exploring immune-related genes and their expression changes in myocardial ...

The dual SGLT1/2 inhibitor sotagliflozin (Inpefa) reduced the risk for myocardial infarction (MI) and stroke in high-risk ...

Risk of long-term mortality is independently associated with eosinophil counts 5 to 7 days after onset in patients with acute myocardial infarction.

A 17-year analysis found sex-based differences in the prevalence and treatment of patients with ST-segment elevation MI with nonobstructive coronary arteries, but the mortality risk remains similar.

Researchers at the University of Toronto's Institute of Biomedical Engineering have found that studying blood flow in leg ...

A new study published in the Journal of the Society for Cardiovascular Angiography & Interventions has revealed a lower risk ...

For patients with acute myocardial infarction (MI) and anemia, 30-day mortality and MI did not differ between restrictive ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.